Anaplastic lymphoma kinase inhibitors - Pipeline Insight, 2024

This “Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Anaplastic Lymphoma Kinase (ALK) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Anaplastic Lymphoma Kinase (ALK) Inhibitors Understanding

Anaplastic Lymphoma Kinase (ALK) Inhibitors: Overview

The anaplastic lymphoma kinase (ALK) receptor is a membrane-bound tyrosine kinase. The pathogenesis of several cancers is closely related to aberrant forms of ALK or aberrant ALK expression, including ALK fusion proteins, ALK-activated point mutations, and ALK amplification. Clinical applications of different ALK inhibitors represent significant progress in targeted therapy.

Function - The receptor ALK plays a pivotal role in cellular communication and in the normal development and function of the nervous system. This observation is based on the extensive expression of ALK messenger RNA (m RNA) throughout the nervous system during mouse embryogenesis. In vitro functional studies have demonstrated that ALK activation promotes neuronal differentiation of PC12 or neuroblastoma celllines.

Anaplastic Lymphoma Kinase (ALK) Inhibitors - ALK inhibitors are anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation. They fall under the category of tyrosine kinase inhibitors, which work by inhibiting proteins involved in the abnormal growth of tumour cells. All the current approved ALK inhibitors function by binding to the ATP pocket of the abnormal ALK protein, blocking its access to energy and deactivating it. A majority of ALK-rearranged NSCLC harbour the EML4-ALK fusion.

Anaplastic Lymphoma Kinase (ALK) Inhibitors Emerging Drugs Chapters

This segment of the Anaplastic Lymphoma Kinase (ALK) Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Anaplastic Lymphoma Kinase (ALK) Inhibitors Emerging Drugs

Ensartinib: Betta Pharmaceuticals Ensartinib hydrochloride is a potent and highly selective next-generation ALK inhibitor with independent intellectual property rights, and it is developed jointly by Betta Pharmaceuticals Co., Ltd. and its subsidiary Xcovey Holding, Inc. (Xcovery). Ensartinib hydrochloride is another product following the EGFR-TKI in Betta’s lung cancer pipeline, and it is expected to be the first innovative targeted drug for lung cancer which is launched globally by a Chinese company. Currently, it is in phase 3 stage of development for the treatment of Non-small cell lung cancer.

TPX 0131: Turning Point Therapeutics TPX-0131 is a next-generation ALK inhibitor entering IND-enabling studies. It has been designed with a novel compact macrocyclic structure and has shown preclinical potent inhibition of wildtype and numerous ALK mutations, including the clinically observed G1202R solvent-front mutation and the G1202R/L1196M compound mutation. Currently, it is in phase ½ of development stage for the treatment of Non-small cell lung cancer.

Anaplastic Lymphoma Kinase (ALK) Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Anaplastic Lymphoma Kinase (ALK) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Anaplastic Lymphoma Kinase (ALK) Inhibitors

There are approx. 15+ key companies which are developing the Anaplastic Lymphoma Kinase (ALK) Inhibitors. The companies which have their Anaplastic Lymphoma Kinase (ALK) Inhibitors drug candidates in the most advanced stage, i.e. phase III include, Betta Pharmaceuticals.

Phases

This report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Anaplastic Lymphoma Kinase (ALK) Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Anaplastic Lymphoma Kinase (ALK) Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anaplastic Lymphoma Kinase (ALK) Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anaplastic Lymphoma Kinase (ALK) Inhibitors drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Anaplastic Lymphoma Kinase (ALK) Inhibitors R&D. The therapies under development are focused on novel approaches for Anaplastic Lymphoma Kinase (ALK) Inhibitors.

Anaplastic Lymphoma Kinase (ALK) Inhibitors Report Insights

• Anaplastic Lymphoma Kinase (ALK) Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Anaplastic Lymphoma Kinase (ALK) Inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Anaplastic Lymphoma Kinase (ALK) Inhibitors drugs?
• How many Anaplastic Lymphoma Kinase (ALK) Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Anaplastic Lymphoma Kinase (ALK) Inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Anaplastic Lymphoma Kinase (ALK) Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Anaplastic Lymphoma Kinase (ALK) Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Betta Pharmaceuticals
• Turning Point Therapeutics
• Nuvalent
• Roche
• Lego ChemBiosciences
• Pfizer
• Qilu Pharmaceutical
• Ascentage Pharma
• Suzhou Zelgen Biopharmaceuticals
• Chia Tai Tianqing Pharmaceutical Group
• Beijing Pearl Biotechnology
• Novartis

Key Products

• Ensartinib
• TPX 0131
• NVL 655
• Alectinib
• RF A089
• Lorlatinib
• WX 0593
• APG 2449
• Crizotinib
• Alkotinib
• TQ-B3139
• PLB1003
• Ceritinib

This product will be delivered within 1-3 business days.